{"filings":[{"id":70522,"accession_number":"0001522767-26-000070","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2026-05-13T21:13:09+00:00","items":["2.02","9.01"],"status":"ready","headline":"MariMed Q1 revenue $39.5M (+4.2% YoY); net loss narrows to $3.8M; adj. EBITDA $3.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $39.5M, up 4.2% YoY from $37.9M.","GAAP net loss $3.8M, improved from $5.5M loss in prior year.","Non-GAAP net loss $3.2M, improved from $3.9M.","Adjusted EBITDA $3.6M (9% margin) vs $2.5M (7% margin) YoY.","Gross margin slightly declined: GAAP 39% (vs 40%), Non-GAAP 40% (vs 41%)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104989,"accession_number":"0001522767-26-000027","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MariMed reports FY2025 revenue of $159.8M, net loss widens to $14.5M, adjusted EBITDA down to $16.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 revenue $159.8M, up from $157.7M in FY2024; Q4 revenue $41.7M vs $38.9M.","GAAP net loss $14.5M in FY2025 vs $12.4M; Non-GAAP adjusted EBITDA $16.9M, down from $19.3M.","Wholesale revenue increased 11%; distribution reached 85% of dispensaries in core markets.","Betty's Eddies ranked #1 edible in MA, MD, DE, IL; restructured Series B debt, extending maturity 4.6 years.","CEO cites growth drivers for 2026: Delaware adult-use, Maine brand licensing, new Columbus OH dispensary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104988,"accession_number":"0001522767-26-000011","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["1.01","2.03","3.02","5.03","9.01"],"status":"ready","headline":"MariMed restructures $14.2M Series B obligation with $8M notes and 26.9M preferred shares","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Old Series B preferred (4,908,333 shares) cancelled, avoiding ~$14.2M cash payout upon mandatory conversion on Feb 28, 2026.","Issued $2M note due March 2028 at 8% and $6M note due March 2031 at 10% (reduces to 8% if $2M note repaid within 6 months).","Issued 26.9M shares of new Series B Convertible Preferred Stock with $0.25/sh liquidation preference ($6.725M aggregate).","New preferred ranks senior to common on dividends/liquidation; conversion options with VWAP-based mechanics.","Restructuring extinguished all prior obligations to Navy Capital Green; no stockholder approval was required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121232,"accession_number":"0001522767-25-000222","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MariMed Q3 revenue $40.8M, adjusted EBITDA $5.1M; expands brands to 3 new states","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue flat at $40.8M (Q3 2024: $40.6M); GAAP net loss widened to $2.9M from $1.0M.","Adjusted EBITDA rose to $5.1M from $4.7M; margin improved to 13% from 12% YoY.","Sequential growth in wholesale and retail; new brand distribution agreements in Maine, Pennsylvania, and New York.","Delaware adult-use sales launched; Metropolis, IL location impacted by new competition.","Nine-month revenue $118.2M vs $118.8M; GAAP net loss $9.8M vs $4.2M."],"consensus_eps_estimate":-0.0102,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":118176000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137881,"accession_number":"0001522767-25-000167","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MariMed Q2 revenue $39.6M, adjusted EBITDA $4.9M; net loss narrows YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $39.6M for Q2 2025, down 2% YoY from $40.4M; GAAP net loss improved to $1.3M from $1.6M.","Non-GAAP adjusted EBITDA of $4.9M (12% margin), up from $4.4M (11% margin) in Q2 2024; company was cash flow positive.","CEO cites 'Expand the Brand' strategy; growth in Massachusetts, full-quarter Delaware contributions, and entry into Pennsylvania.","Six-month net loss widened to $6.7M from $2.9M, while non-GAAP net loss also widened; adjusted EBITDA margin fell to 10%.","Company anticipates catalysts in H2: adult-use Delaware, new Maine license, Pennsylvania entry, and M&A optionality."],"consensus_eps_estimate":-0.0102,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":77566000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155265,"accession_number":"0001522767-25-000130","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MariMed shareholders re-elect four directors and ratify auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Four directors re-elected: Jon R. Levine, Edward Gildea, David Allen, Eva Selhub, each with >107M votes for.","Advisory approval of M&K CPAs PLLC as auditor for FY2025: 204M for, 10.5M against, 4.6M abstain.","Broker non-votes of ~103.5M shares on director election reflect shares not voted on management proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155264,"accession_number":"0001522767-25-000048","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MariMed Q1 revenue flat at $38.0M; net loss widens to $5.4M from $1.3M YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $38.0M flat vs $37.9M a year ago; GAAP gross margin fell to 40% from 43%.","GAAP net loss of $5.4M widened from $1.3M loss; Non-GAAP net loss $3.8M vs $0.6M.","Non-GAAP Adjusted EBITDA dropped to $2.6M (7% margin) from $4.7M (12% margin).","Wholesale sales rose to 44% of revenue; 70 new storefronts added; Betty's Eddies top edible in MA, MD, DE.","Management cites soft retail quarter, ramp-up costs in IL and MO; eyes M&A, licensing, hemp entry."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":37955000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173776,"accession_number":"0001522767-25-000010","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MariMed reports record FY2024 revenue $158M; Q4 margins compress, adjusted EBITDA up in Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $39.0M (vs $38.9M); full-year revenue $158.0M (+6.3% YoY).","GAAP gross margin fell to 33% in Q4 from 45% YoY; full-year margin 40% vs 44%.","Full-year GAAP net loss improved to $12.1M from $16.0M; adjusted EBITDA $19.6M vs $24.7M.","Wholesale revenue up 29% annually; Betty's Eddies top-selling edible in MA and MD.","CEO cites 10 revenue-generating assets added over past two years for 2025 growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190761,"accession_number":"0001522767-24-000088","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MariMed Q3 revenue up 5% to $40.6M; net loss narrows to $1.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $40.6M, +5% YoY; adjusted EBITDA $4.7M vs $6.1M in Q3 2023.","GAAP net loss $1.0M improved from $4.3M loss; non-GAAP net income $0.5M.","Wholesale revenue grew at least 20% YoY; retail transactions increased YoY.","Nine-month revenue $119.0M, up 8.5% YoY; adjusted EBITDA $13.7M vs $19.4M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":118962000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207237,"accession_number":"0001522767-24-000069","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"MariMed appoints Mario Pinho as CFO; 300,000 RSU inducement award","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective Aug 9, 2024, Mario Pinho named CFO, replacing interim CFO Jon Levine.","Pinho receives 300,000 RSUs inducement award, $265K base salary, and 30% performance bonus.","Levine remains President and CEO of MariMed.","Pinho, 57, CPA, previously CFO at Rakuten USA (2016-2024) and senior roles at American Express and KPMG."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207236,"accession_number":"0001522767-24-000063","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MariMed Q2 2024 revenue $40.4M, GAAP net loss $1.6M, adjusted EBITDA $4.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $40.4M, up 10.7% YoY from $36.5M; gross margin 42% (GAAP), 43% (non-GAAP).","GAAP net loss $1.6M vs loss $0.9M in Q2 2023; non-GAAP net loss $0.2M vs income $0.6M.","Non-GAAP adjusted EBITDA $4.4M (11% margin), down from $6.3M (17% margin) a year ago.","Retail transactions increased 24% YoY; wholesale segment led overall growth.","Management reaffirms 2024 financial targets; expects margin expansion and improved cash flow."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":78371000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224607,"accession_number":"0001522767-24-000045","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MariMed stockholders re-elect five directors and approve auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Re-elected Jon R. Levine, Edward Gildea, David Allen, Eva Selhub, and Kathleen Tucker as directors.","Advisory approval of M&K CPAs PLLC as independent auditors for fiscal 2024 with 205.2M votes for.","Meeting held June 6, 2024; all proposals passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224606,"accession_number":"0001522767-24-000040","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MariMed Q1 2024 revenue up 10% to $37.9M; net loss widens to $1.3M, adjusted EBITDA down","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $37.9M (+10% YoY); GAAP gross margin 43% vs 45% in prior year.","GAAP net loss $1.3M (vs $0.7M loss); non-GAAP net loss $0.6M (vs $0.3M income).","Adjusted EBITDA $4.7M vs $7.1M; margin 12% vs 21%; CEO cites wholesale growth.","17th consecutive quarter of positive adjusted EBITDA; management reaffirms strategic plan."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":37933000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243902,"accession_number":"0001522767-24-000005","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2024-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MariMed Q4 revenue $38.9M (+8.6% YoY); GAAP net loss $10.1M; announces MD dispensary acquisition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $38.9M, up 8.6% from $35.8M in Q4 2022; full year revenue $148.6M, up 10.9% from $134.0M.","GAAP net loss of $10.1M in Q4 vs net income of $4.8M in prior year; full year net loss $16.0M vs net income $13.6M.","Non-GAAP adjusted EBITDA $5.2M in Q4 (14% margin) vs $4.5M in Q4 2022; full year $24.7M (17% margin) vs $32.4M (24% margin).","Company announces pending acquisition of a dispensary in Upper Marlboro, Maryland, expanding its footprint in the state.","CEO cites sixth consecutive year of double-digit revenue growth and positive adjusted EBITDA; wholesale operations in Illinois contributing to 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}